{"groups":[{"description":"Participants received 40 milligrams (mg) cabozantinib oral tablets once daily + 1200 mg intravenous (IV) infusion of atezolizumab once every 3 weeks for up to 38 months.","id":"FG000","title":"Experimental Arm: Cabozantinib + Atezolizumab"},{"description":"Participants received 60 mg cabozantinib oral tablets once daily for up to 38 months.","id":"FG001","title":"Single-Agent Cabozantinib"},{"description":"Participants received 400 mg sorafenib oral tablets twice daily (BID) for up to 38 months.","id":"FG002","title":"Control Arm: Sorafenib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"10"}],"type":"Did not receive any study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"204"},{"groupId":"FG001","numSubjects":"92"},{"groupId":"FG002","numSubjects":"115"}],"type":"Radiographic progression"},{"reasons":[{"groupId":"FG000","numSubjects":"140"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"51"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"24"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"7"}],"type":"Sponsor decision,"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Other than specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"432"},{"groupId":"FG001","numSubjects":"188"},{"groupId":"FG002","numSubjects":"217"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"429"},{"groupId":"FG001","numSubjects":"188"},{"groupId":"FG002","numSubjects":"207"}],"type":"Received At Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"432"},{"groupId":"FG001","numSubjects":"188"},{"groupId":"FG002","numSubjects":"217"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}